A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

Assessment of treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases. The count of circulating tumor cells (CTCs) is a promising surrogate marker that may replace the widely used prostate-specific antigen (PSA). The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilbaux, M, Tod, M, De Bono, J, Lorente, D, Mateo, J, Freyer, G, You, B, Hénin, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452933/
https://www.ncbi.nlm.nih.gov/pubmed/26225253
http://dx.doi.org/10.1002/psp4.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452933/
https://www.ncbi.nlm.nih.gov/pubmed/26225253
http://dx.doi.org/10.1002/psp4.34

Ejemplares similares